Silexion Therapeutics has reported promising preclinical results for its RNA interference (RNAi) therapeutic candidate, SIL-204, targeting KRAS-driven pancreatic cancers. In orthotopic pancreatic cancer models, where human tumor cells are implanted directly into the pancreas to closely mimic human disease progression, systemic administration of SIL-204 led to significant tumor reductions. Specifically, studies demonstrated approximately a 70% reduction in tumor cell numbers in the AsPC-1 model (harboring the KRAS G12D mutation) and an 80% reduction in the BxPC-3 model (KRAS wild-type) over a 28-day period.
These findings underscore SIL-204’s potential as an effective systemic treatment for pancreatic cancer, addressing various KRAS mutation profiles. The success of SIL-204 in these preclinical models represents a significant advancement in RNAi therapeutics for pancreatic cancer, a disease known for its aggressiveness and poor prognosis. The company plans to further investigate SIL-204’s impact on metastasis and its efficacy across a broader range of KRAS mutations, aiming to enhance therapeutic options for patients battling this challenging cancer.
